Progentec Announces Research Collaboration with GSK to Assess Proteomics and Digital Health Tools for Lupus (SLE) Care
OKLAHOMA CITY, June 8, 2021 /PRNewswire/ -- Progentec, a leader in diagnostic and digital technologies for the proactive management of autoimmune diseases, announced today an 18-month collaborative research agreement with GlaxoSmithKline (GSK) to evaluate novel measurement and management tools for systemic lupus erythematosus ("SLE" or "lupus").
At least 5 million people worldwide are living with lupus, one of the most complex autoimmune diseasesi. It's difficult to diagnose and even more challenging to treatii. The condition is associated with a range of debilitating symptoms that can fluctuate over time, including painful or swollen joints, extreme fatigue, unexplained fever, skin rashes, and organ damageii. Up to 50% of SLE patients experience irreversible organ damage within five years of diagnosis and this damage is associated with a poor long-term prognosis and early mortalityiii iv v
Patient-generated data, including data from wearable devices, is becoming an integral part of chronic disease care as it enables continuous monitoring of pertinent health signals both in and outside of the clinic. These signals increase in predictive value when combined with artificial intelligence (AI) algorithms and lupus-specific laboratory testing. The research agreement between Progentec and GSK supports two United States-based studies that will evaluate how new-to-market clinical tools, including proteomics and digital health, may help achieve a more proactive approach to lupus management.
"For too long, precision medicine has been a buzzword when it comes to caring for Lupus Warriors," said Mohan Purushothaman, Ph.D., Chairman and CEO of Progentec. "This research has the potential to show how both immunological data and patient-generated data can support clinicians as they identify the optimal treatment for each lupus patient."
Both studies are scheduled to start in 2021, and the findings and results will be submitted as abstracts for presentation at scientific congresses and manuscripts for publication in peer-reviewed journals.
Learn more about using aiSLE™ MGMT by visiting https://progentec.com/aisle-mgmt
About Progentec Diagnostics, Inc.
Statements contained herein that are not historical facts are forward-looking statements that represent management's beliefs and assumptions as of the date of this news release based on currently available information. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements.
i Lupus Foundation of America. Lupus facts and statistics. Available at: https://www.lupus.org/resources/lupus-facts-and-statistics. Last accessed December 2019
Contact: Brett Adelman
View original content to download multimedia:http://www.prnewswire.com/news-releases/progentec-announces-research-collaboration-with-gsk-to-assess-proteomics-and-digital-health-tools-for-lupus-sle-care-301307152.html
SOURCE Progentec Diagnostics, Inc.